Erythropoietin in heart failure: Pathology and protection

Research output: ThesisThesis fully internal (DIV)

202 Downloads (Pure)


Anemia is common in chronic heart failure (CHF) patients and related to impaired survival. The etiology of anemia in CHF-patients is often unknown. We hypothesized that dysregulation of erythropoietin (EPO) synthesis by the kidney or an altered sensitivity of the bone marrow to EPO might represent causes specific for CHF. In addition, recombinant human EPO (rhEPO) has been shown to improve cardiac function in heart failure. We hypothesized that EPO-induced improvement of cardiac function is mediated through mechanisms that are unrelated to increases in hematocrit levels. In the present thesis we explored EPO as a pahthophysiological factor in anemia and the mechanisms of its ancillary beneficial cardiac effects in heart failure.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • University of Groningen
  • van Veldhuisen, Dirkjan, Supervisor
Award date17-Sept-2008
Print ISBNs9789036735193
Publication statusPublished - 2008

Cite this